3.83
+1.59%
Close of 19 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
Price performance
Chart by TradingView, with its own licensed prices
- Market value
- $94.0m
- Last close × shares
- Volume
- 773.2k
- Shares, 19 Nov 2026
About Artiva Biotherapeutics
From its filings with the US Securities and Exchange Commission
Artiva Biotherapeutics is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ARTV. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $83.9m. At that date it held total assets of $130.9m and shareholders' equity of $110.0m.
We are a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic) rather than a patient’s own cells (autologous) and are pre-manufactured and stored frozen and ready to ship to a patient’s treatment location, making them what we believe to be “off-the-shelf.” Our lead product candidate, AlloNK (also known as AB-101), is an allogeneic, non-genetically modified, cryopreserved NK cell therapy designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of monoclonal antibodies (mAbs) to drive B-cell depletion. We are currently evaluating AlloNK in three ongoing clinical trials for the treatment of B-cell driven autoimmune diseases, including a company-sponsored basket trial across autoimmune diseases that includes rheumatoid arthritis (RA) and Sjögren’s disease (SjD). We are prioritizing refractory RA as our lead indication for AlloNK development. We expect to share initial clinical response data across dose levels from more than 15 refractory RA patients, several of whom will have 6 months or more follow up, in the first half of 2026. In addition, we plan to conduct FDA regulatory interactions in the first half of 2026 to align on the pivotal trial design for AlloNK in refractory RA.
Quoted from its 10-K, filed 10 Mar 2026. Read the filing on SEC.gov ↗
Latest on Artiva Biotherapeutics
Our reporting
- Artiva Biotherapeutics falls 2.33% in Wednesday's session
- Artiva Biotherapeutics falls 2.53% in Tuesday's session
- Artiva Biotherapeutics falls 2.70% in Thursday's session
- Artiva Biotherapeutics falls 3.79% in Tuesday's session
- Artiva Biotherapeutics falls 4.47% in Thursday's session
- Artiva Biotherapeutics rises 11.38% in Tuesday's session
Next results
Due on 9 Mar 2027. Analysts expect earnings of -0.56 a share.
Other Health Care listings
Scenario calculator
Try your own numbers. This is arithmetic, not a forecast.
Gain or loss
Return
Leaves out fees, taxes and financing.
Frequently asked questions
What is Artiva Biotherapeutics's ticker?
Artiva Biotherapeutics trades as ARTV on its US listing, under ISIN US04317A1079.
What was Artiva Biotherapeutics's last closing price?
3.83 on 19 Nov 2026. The figure is in USD and is never converted.
When does Artiva Biotherapeutics next report results?
Results are expected on 11 Nov 2026, according to our data supplier.
Sources and methodology
- Chart
- TradingView
- Close and company data
- SEC filings and our data supplier
- News
- Our reporting
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.